Ketamine Side Effects: A Complete Clinical Guide

Ketamine side effects during low-dose (subanesthetic) therapy are acute, dose-dependent, and typically resolve within one to two hours after treatment, unlike the days-to-weeks side effect profile of SSRIs or the respiratory and gastrointestinal risks associated with opioids. Ketamine is a dissociative anesthetic and NMDA receptor antagonist that blocks glutamate signaling at the N-methyl-D-aspartate receptor; at low, subanesthetic doses it is used off-label for treatment-resistant depression, chronic pain, and other conditions. The most common ketamine side effects are dissociation, transient blood pressure and heart rate elevation, nausea, and short-term cognitive slowing. This guide reviews the full side effect profile organized by body system, with incidence rates, mechanisms, risk factors, and management strategies drawn from clinical trial data and consensus monitoring guidelines. The reference dose throughout is the standard 0.5 mg/kg intravenous infusion given over 40 minutes, or the equivalent dose delivered by intramuscular, sublingual, or oral routes.

Dissociation is the defining pharmacological effect of low-dose ketamine and the side effect least familiar to patients accustomed to conventional psychiatric or pain medications. According to a systematic review by Short and colleagues (2018), dissociative symptoms of at least mild intensity occur in approximately 60 to 80 percent of patients receiving the standard 0.5 mg/kg intravenous dose. The experience spans several distinct phenomena: derealization, where the environment feels unreal or dreamlike; depersonalization, a sense of detachment from one's own body or thoughts; altered time perception; a blurring of the boundary between self and environment; and perceptual distortions in size, shape, or color. Patients often describe it as floating, being in a dream, or watching themselves from a distance.

Whether dissociation is simply a side effect or an active part of ketamine's antidepressant mechanism remains an open question. Dissociation intensity is measured clinically with the Clinician-Administered Dissociative States Scale (CADSS), a 23-item, clinician-rated tool that scores the severity of derealization, depersonalization, and amnesia. Luckenbaugh and colleagues (2014) found that higher CADSS scores correlated with stronger antidepressant response in their sample, though other trials have failed to replicate that association. Regardless of its mechanistic role, dissociation is the leading source of patient anxiety about ketamine treatment, and thorough pre-treatment counseling that normalizes the experience reduces distress substantially.

Dissociative symptoms typically begin 5 to 10 minutes after an infusion starts, peak around 15 to 30 minutes, and resolve within 60 to 90 minutes of infusion completion. Sublingual and oral doses produce a more gradual onset and a longer duration of milder dissociation, a difference covered in more detail in how long ketamine's effects last by route. By two hours post-treatment, fewer than 5 percent of patients report residual dissociative symptoms.

Clinicians can reduce dissociation intensity by slowing the infusion rate to 50 or 60 minutes, lowering the dose to 0.35-0.4 mg/kg, or using environmental measures such as eye masks, calming music, dimmed lighting, and a trained staff member present throughout. Pretreatment with a low-dose benzodiazepine, such as midazolam 1-2 mg or lorazepam 0.5 mg, also reduces dissociation but has been linked to attenuated antidepressant response in some studies; see ketamine and benzodiazepines for a fuller look at that tradeoff.

Nausea is the second most common ketamine side effect, occurring in about 15 to 30 percent of patients receiving IV infusions; vomiting is less frequent, reported in 5 to 10 percent. The mechanisms are multifactorial: direct stimulation of dopamine and serotonin receptors in the chemoreceptor trigger zone, a brainstem region that detects circulating toxins and triggers vomiting; vestibular disturbance related to the dissociative state; and autonomic activation from ketamine's sympathomimetic effects. Risk factors include female sex, a history of motion sickness or postoperative nausea, younger age, and eating shortly before treatment. Oral and sublingual doses produce higher nausea rates than IV administration because of added gastrointestinal mucosal irritation, a consideration covered in the troche dosage guide.

Prophylactic ondansetron 4 mg given 30 minutes before infusion is the first-line antiemetic strategy and reduces nausea incidence by an estimated 40 to 60 percent in high-risk patients, according to consensus guidelines from Cohen and colleagues (2018). Fasting for two to four hours before treatment, supine positioning, minimal head movement, and reduced sensory stimulation are effective non-drug adjuncts.

Ketamine releases catecholamines and blocks their neuronal reuptake, which produces measurable but usually well-tolerated hemodynamic changes at subanesthetic doses. During a standard 0.5 mg/kg infusion, systolic blood pressure typically rises 15 to 25 mmHg, diastolic pressure rises 10 to 15 mmHg, and heart rate increases 10 to 20 beats per minute, according to a clinical analysis by Wan and colleagues (2015). These changes peak during or shortly after infusion and return to baseline within 60 to 120 minutes.

Because of this profile, structured vital sign monitoring is standard practice: measurements at baseline, every 15 minutes during infusion, and every 30 minutes for one to two hours afterward, a protocol detailed further in cardiovascular monitoring during ketamine treatment. Patients with known structural heart disease, congestive heart failure, or a history of arrhythmia should have cardiology clearance before starting ketamine therapy, although these conditions are not automatic disqualifiers at low doses. Ketamine does not meaningfully prolong the QTc interval, the portion of the cardiac cycle associated with arrhythmia risk with several other psychiatric medications, and it does not cause the orthostatic hypotension common to many antidepressants.

Beyond dissociation, 40 to 60 percent of patients report sensory-perceptual changes during infusion: blurred vision, enhanced or altered color perception, geometric patterns, or apparent movement of stationary objects, along with muffled hearing, echoing voices, or heightened sensitivity to sound. These reflect ketamine's effect on sensory processing in the thalamus and cortex and are distinct from true hallucinations because patients generally retain awareness that the perceptions are drug-induced. At higher doses or in susceptible individuals, more vivid phenomena approaching formed hallucinations can occur and should prompt a dose reassessment.

Numbness, tingling, and a sense of heaviness or lightness in the extremities are also common during and immediately after infusion, resulting from NMDA receptor blockade in the somatosensory cortex. These sensations are self-limiting and do not indicate a neurological problem.

During and for several hours after treatment, patients experience measurable, dose-dependent impairment in attention, working memory, executive function, and processing speed. This impairment typically resolves within two to four hours, though some residual slowing can persist up to 24 hours. It is the basis for the standard restriction that patients not drive, operate machinery, or make significant financial or legal decisions for at least 24 hours after treatment, a restriction that applies equally to at-home oral formulations.

Studies of therapeutic ketamine over six- to twelve-month courses have not shown progressive cognitive decline, in contrast to chronic recreational users, who show dose-dependent impairment in episodic memory and executive function at far higher cumulative doses. Periodic cognitive screening is still reasonable for patients on long-term maintenance therapy, particularly older adults.

About 10 to 20 percent of patients experience transient anxiety, agitation, or dysphoria during infusion, most often at treatment onset and most common in treatment-naive patients or those with comorbid anxiety disorders. Education, expectation-setting, and a calm, private, consistently staffed treatment environment are the primary management tools. A brief anxiolytic premedication such as hydroxyzine 25 mg can be considered for severe anticipatory anxiety, though benzodiazepines carry the same efficacy tradeoff described above.

Ketamine can also produce brief euphoria or a sense of interconnectedness, which contributes to its abuse potential and warrants clinical awareness, particularly in patients with a current or past substance use disorder. These patients benefit from directly observed administration and urine drug screening; combined medication and substance use history is covered further in ketamine drug interactions.

Emergence reactions, vivid or occasionally frightening mental experiences during recovery, are well documented in anesthetic practice and occur less commonly at subanesthetic doses. They are more likely with rapid IV administration or higher doses and are usually managed with a calm recovery environment and reassurance.

Long-term, high-frequency ketamine use, primarily documented in recreational users consuming multiple grams daily over months or years, is associated with an inflammatory cystitis marked by bladder pain, urinary frequency and urgency, dysuria, and hematuria; severe cases can progress to a contracted bladder with reduced capacity. At therapeutic low doses and typical treatment frequencies, clinically significant cystitis is rare. Clinicians should still ask about lower urinary tract symptoms at each follow-up visit and refer promptly for any new urinary complaints, since early detection and dose adjustment can prevent progression.

Chronic ketamine exposure can also elevate liver transaminases and, rarely, cause cholestatic liver injury. Routine liver function testing every three to six months during maintenance therapy is recommended, and patients with pre-existing liver disease may need more cautious dosing and closer monitoring.

Post-treatment headache affects roughly 15 to 25 percent of patients, usually mild to moderate and responsive to acetaminophen or NSAIDs; it tends to decrease with successive treatments. Fatigue is reported by 20 to 30 percent of patients, and most prefer to rest for one to two hours after treatment, though some describe a later sense of energization tied to acute mood improvement. Dizziness, imbalance, and gait unsteadiness are common in the immediate post-infusion period, reflecting effects on vestibular and cerebellar function, and typically resolve within 60 to 90 minutes; patients should remain seated or supervised until they do. Ketamine also increases salivary secretions through its effect on muscarinic receptors; this is rarely bothersome at low doses but can be managed with glycopyrrolate 0.2 mg IV if needed.

A standardized monitoring protocol tracks vital signs, blood pressure, heart rate, respiratory rate, and oxygen saturation, at baseline, every 15 minutes during infusion, and every 30 minutes post-infusion until discharge criteria are met. Dissociation is assessed at peak effect using the CADSS or a simplified clinical rating, and side effects are documented at each visit using a checklist or severity scale. Discharge requires that the patient is oriented to person, place, and time; ambulatory without assistance; within 20 percent of baseline blood pressure; free of active nausea or vomiting; and has a responsible adult present for transport home.

This review draws on the following sources: Short and colleagues (2018), a systematic review quantifying side effect incidence across ketamine depression trials; Cohen and colleagues (2018), consensus guidelines for IV ketamine infusions in chronic pain covering monitoring and safety parameters; Wan and colleagues (2015), a clinical analysis of hemodynamic changes during low-dose ketamine administration; Luckenbaugh and colleagues (2014), a study examining the relationship between acute dissociation and antidepressant response; the FDA's approval announcement and prescribing information for Spravato (esketamine), which includes adverse event data from pivotal trials; and the National Institute of Mental Health's overview of depression research, which provides context on ketamine's safety and tolerability profile.